计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
R411995-1mg |
1mg |
期货 ![]() |
| |
R411995-5mg |
5mg |
期货 ![]() |
| |
R411995-10mg |
10mg |
期货 ![]() |
|
产品名称 | Ramucirumab (anti-VEGFR2) |
---|---|
别名 | IMC-1121B, LY3009806, IMC-1121; CD309 antibody; CD309 antigen antibody; EC 2.7.10.1 antibody; Fetal liver kinase 1 antibody; FLK-1 antibody; FLK1 antibody; FLK1, mouse, homolog of antibody; Kdr antibody; Kinase insert domain receptor (a type III receptor |
英文别名 | IMC-1121B, LY3009806, IMC-1121; CD309 antibody; CD309 antigen antibody; EC 2.7.10.1 antibody; Fetal liver kinase 1 antibody; FLK-1 antibody; FLK1 antibody; FLK1, mouse, homolog of antibody; Kdr antibody; Kinase insert domain receptor (a type III receptor |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
特异性 | VEGFR2 |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
反应种属 | Cynomolgus,Human |
偶联标记 | Unconjugated |
抗体类型 | Primary antibody |
---|---|
Format | Whole IgG |
亚型 | Human IgG1 |
轻链亚型 | Kappa |
SDS-PAGE | 26.5 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 176.7 kDa, under non-reducing conditions |
纯化方法 | Protein A purified |
来源 | CHO supernatant |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | Lot by Lot |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | Store at -80℃ long term (18 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS编号和信息 | 947687-13-0 |
IMGT/mAb-DB | 295 |
---|---|
Wikipedia | Ramucirumab |
PubChem SID | 178103962 |
输入批号以搜索COA:
1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. (2002) Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.. Int J Cancer, 97 (3): (393-9). [PMID:11774295] |
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.. J Biol Chem, 278 (44): (43496-507). [PMID:12917408] |
3. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY et al.. (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet Oncol, 20 (2): (282-296). [PMID:30665869] |